Tarsus Pharmaceuticals, Inc.
TARS
Kedudukan dalam Saham
#4606
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
Harga Saham
$70.89
Modal Pasaran
$3.32B
Perubahan (1 hari)
2.00%
Perubahan (1 tahun)
-0.42%
Negara
US
Perdagangan Tarsus Pharmaceuticals, Inc. (TARS)
Kategori
Healthcare
Nisbah P/S bagi Tarsus Pharmaceuticals, Inc. (TARS)
Nisbah P/S pada October 2026 TTM: 5.13
Menurut laporan kewangan dan harga saham terkini Tarsus Pharmaceuticals, Inc., nisbah P/S semasa (TTM) ialah 5.13. Pada akhir 2023, nisbah P/S syarikat ialah 34.10.
Sejarah nisbah P/S untuk Tarsus Pharmaceuticals, Inc. dari 2018 hingga 2026
Nisbah P/S pada akhir setiap tahun
| Tahun | Nisbah P/S | Ubah |
|---|---|---|
| 2026 (TTM) | 5.13 | -54.93% |
| 2024 | 11.38 | -66.63% |
| 2023 | 34.10 | 143.94% |
| 2022 | 13.98 | 72.40% |
| 2021 | 8.11 | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
Nisbah P/S untuk syarikat atau pesaing yang serupa
| Syarikat | Nisbah P/S | Perbezaan Nisbah P/S | Negara |
|---|---|---|---|
| 10.02 | 95.38% |
US
|
|
| 40.55 | 690.54% |
US
|
|
| 3.96 | -22.78% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | 97.80% |
NL
|
